Norway· NO-ID_D4FED77F-5B84-4727-BF10-613804F75222
Neupogen
A filgrastim product containing filgrastim, registered in Norway by Ukjent (2). The same ATC class is registered in 17 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Filgrastim is registered in 17 of 19 countries.
Countries holding a registration under ATC L03AA02 (filgrastim), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Filgrastim · ATC L03AA02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Filgrastim
- Manufacturer
- Ukjent (2)
- Country
- Norway (NO)
- ATC code
- L03AA02
- ATC class
- Filgrastim
- Defined daily dose
- 0.35 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
- no_merkevare_idID_D4FED77F-5B84-4727-BF10-613804F75222
- no_varenummer2184615 x 1
- gtin8715131020125
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
191 interactions on record for filgrastim.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Filgrastim · interactions on record
191 records
- 2 severe
- 189 moderate
Most severe, free to view
- CladribineL01BB04severe
- CyclophosphamideL01AA01moderate
- ChlorambucilL01AA02moderate
- MelphalanL01AA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Filgrastim in 18 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- DenmarkNeupogenAmgen Europe BV
- SpainNEUPOGEN 30 MU (0,3 mg/ml) SOLUCION INYECTABLEAmgen Europe B.V.
- SwedenNeupogen 0,3 mg/ml Injektionsvätska, lösningAmgen Europe B.V.
- CzechiaACCOFILAccord Healthcare S.L.U., Barcelona
- FinlandAccofilAccord Healthcare S.L.U.
- United StatesFILKRIAccord BioPharma Inc.,
- BelgiumAccofil 12 10*6 U/0.2 mlAccord Healthcare
- PolandAccofilAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Belgium · Neupogen
- Germany · Neupogen
- Spain · Neupogen
- France · Neupogen
- United Kingdom (Northern Ireland) · Neupogen, Neupogen Singleject
- Ireland · Neupogen, Neupogen Singleject
- Iceland · Accofil, Filgrastim Hexal
- Italy · Granulokine
- Liechtenstein · Accofil, Filgrastim Hexal
- Luxembourg · Neupogen
- Netherlands · Neupogen, Neupogen Singleject
- Poland · Neupogen
- Sweden · Neupogen
- Slovenia · Neupogen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f878b5e5-cbc4-4e99-9500-6b59431b3799 GET /v1/drugs/f878b5e5-cbc4-4e99-9500-6b59431b3799?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Filgrastim",
"merkevare_id": "ID_D4FED77F-5B84-4727-BF10-613804F75222",
"name_form_strength": "Neupogen inj, oppl 0,3 mg/ml",
"prescription_group": "C"
}See everything about filgrastim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.